News and Reports
-
Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
26 June 2014Download -
Basilea’s oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study
2 June 2014Download -
PTC Therapeutics receives positive opinion from CHMP for Translarna? (ATALUREN)
23 May 2014Download -
Ophthotech Corporation Announces Closing of Registered Public Offering of Common Stock Including Full Exercise of Underwriters? Option to Purchase Additional Shares
19 May 2014Download -
Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
8 May 2014Download -
Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
7 May 2014Download -
Curetis Launches Unyvero™ i60 Implant and Tissue Infection Cartridge in Europe
7 May 2014Download -
New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application
23 April 2014Download -
Enanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen
22 April 2014Download -
Revolutionary Spinal Deformity Surgical Treatment is Available in the United States
7 March 2014Download -
Advanced Accelerator Applications enters UK and Irish nuclear medicine markets with the acquisition of Imaging Equipment Ltd
4 March 2014Download -
Basilea swaps its isavuconazole North American copromote rights for full isavuconazole rights outside of North America
28 February 2014Download -
Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
27 February 2014Download -
PTC Therapeutics Announces Closing of Registered Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
19 February 2014Download -
Option to Purchase Additional Shares Offering of Common Stock Including Full Exercise of Underwriters? Option to Purchase Additional Shares
18 February 2014Download -
PTC - Joint program in spinal muscular atrophy enters first stage of clinical development
22 January 2014Download -
Ophthotech closes initial public offering
30 September 2013Download -
Basilea reports positive topline phase 3 results for antifungal isavuconazole
30 September 2013Download -
Nabriva Therapeutics presented data on potency, safety, tolerability and pharmacokinetics of Pleuromutilin antibiotic BC-3781
13 September 2013Download -
Tensys Medical receives CE Mark for TL-400 & TL-300, latest generations in continuous, non-invasive hemodynamic patient monitoring system
3 September 2013Download -
Ophthotech enrolls first patient in phase 3 clinical trial of Fovista™ Anti-PDGF therapy in combination with Anti-VEGF therapy for wet AMD
29 August 2013Download -
Tensys’ TL-300 receives SFDA approval for Chinese market
21 August 2013Download -
Kolltan enters into license and option agreement with MedImmune
29 July 2013Download -
PTC Therapeutics closes initial public offering
25 June 2013Download -
Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072
25 June 2013Download